FAAH Availability in Psychiatric Disorders: A PET Study

Stopped early · Early Phase 1

Conditions studied: Post Traumatic Stress Disorder, Alcohol Use Disorder, Psychosis

In brief

The aim of the present study is to examine Fatty Acid Amide Hydrolase (FAAH) availability in humans, including healthy individuals and across a spectrum of psychiatric disorders in which alterations in the endocannabinoid system are observed.

Key facts

Study ID

NCT04404712

Run by

Yale University

People needed

6

Starts

2020-09-23

Expected to finish

2021-06-30

Last updated by the study team

2023-02-21

Who can join

Age: 18 and older, up to 65. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Between the ages of 18 and 65 years, inclusive
• Good physical health as determined by history, physical and laboratory examinations, ECG, and vital signs
• PTSD Inclusion Criteria:
• Diagnosis of Post-Traumatic Stress Disorder
• AUD Inclusion Criteria:
• Diagnosis of Alcohol Use Disorder
• Psychosis Inclusion Criteria:
• Diagnosis of psychotic disorder such as Schizophrenia, Schizoaffective disorder

You may not qualify if…

• Presence of ferromagnetic metal in the body or heart pacemaker
• Women with a positive pregnancy test or women who are lactating

Where it is running

• Connecticut Mental Health Center — New Haven, Connecticut, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.